Name | Fenoterol |
Synonyms | lcohol opropane Fenoterol 1-(3,5-Dihydroxyphenyl)-2-(p-hydroxy-α-methylphenethylamino)ethanol 3,5-dihydroxy-alpha-(((p-hydroxy-alpha-methylphenethyl)amino)methyl)benzyla 1,3-benzenediol,5-(1-hydroxy-2-((2-(4-hydroxyphenyl)-1-methylethyl)amino)eth 1-(p-hydroxyphenyl)-2-((beta-hydroxy-beta-(3',5'-dihydroxyphenyl))ethyl)amin 1-(3,5-Dihydroxyphenyl)-1-hydroxy-2-[1-(4-hydroxyphenyl)isopropyl]aminoethane benzylalcohol,3,5-dihydroxy-alpha-(((p-hydroxy-alpha-methylphenethyl)amino)me |
CAS | 13392-18-2 |
InChI | InChI=1/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3 |
Molecular Formula | C17H21NO4 |
Molar Mass | 303.35 |
Density | 1.289±0.06 g/cm3(Predicted) |
Melting Point | 181-183°C |
Boling Point | 566.0±45.0 °C(Predicted) |
pKa | pKa 8.5 (Uncertain);10.0 (Uncertain) |
biological activity | Fenoterol (Phenoterol) is a β2 adrenoreceptor agonist with bronchodilating activity. |
Target | Value |
Cell Line: | THP-1 cells stimulated with AICAR |
Concentration: | 1 μM |
Incubation Time: | Pre-incubated 30 minutes |
Result: | Significantly downregulated the elevated phosphorylation levels of AMPK. Alleviated neuropathic allodynia during chronic treatment. |
Animal Model: | Male C57BL/6J mice (6 weeks old) with neuropathy |
Dosage: | 0.7 mg/kg |
Administration: | Intraperitoneal injection; twice a day; for 3 weeks |